Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01543451
Other study ID # TIDE-11-10
Secondary ID
Status Completed
Phase Phase 2
First received February 21, 2012
Last updated February 27, 2014
Start date February 2012
Est. completion date October 2013

Study information

Verified date February 2014
Source Helsinn Healthcare SA
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationBulgaria: Ministry of HealthHungary: National Institute of PharmacyRomania: National Medicines AgencyRussia: Ministry of Health of the Russian Federation
Study type Interventional

Clinical Trial Summary

The main objective of this study will be to obtain data on the efficacy of elsiglutide in preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving 5-FU based chemotherapy (FOLFOX4 or FOLFIRI regimen) in comparison to placebo.


Recruitment information / eligibility

Status Completed
Enrollment 138
Est. completion date October 2013
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Written informed consent;

2. Male or female patient = 18 years of age;

3. Confirmed diagnosis of colorectal cancer;

4. Chemotherapy naïve patient;

5. Patient scheduled to receive a FOLFOX4 or FOLFIRI chemotherapy regimen according to the following scheme and dosage (1st cycle):

AGENT DOSE ROUTE/DURATION DAYS Oxaliplatin or Irinotecan 85/180 mg m2 i.v. infusion/2h 1 FolinicAcid (leucovorin) 200 mg m2 i.v. infusion/2h 1+2 5-Fluorouracil (5FU) 400 mg m2 i.v. bolus 1+2 5-Fluorouracil (5FU) 600 mg m2 i.v. infusion/22h 1+2

6. A performance status of = 2 according to the Eastern Cooperative Oncology Group(ECOG);

7. Non-fertile patient or fertile patient (male or female) using reliable contraceptive measures

8. Female patient of childbearing potential; need to have a negative pregnancy test at screening.

Inclusion criteria 1-8 will be verified at screening.

Inclusion criteria 8 will be re-confirmed on Day 1.

Exclusion Criteria:

1. Inability to understand study procedures and/or cooperate with the study Investigator;

2. Any investigational drugs within 30 days before enrollment in the study or foreseen use of investigational agents during the study;

3. Patient with any type of ostomy;

4. Any previous radiotherapy to the abdomen or pelvis;

5. Scheduled to receive radiotherapy to abdomen or pelvis during the study (Day 1 to Day 14);

6. Scheduled to receive any concomitant chemotherapeutic agent other than FOLFOX4 or FOLFIRI agents (Oxaliplatin, Irinotecan, Folinic acid, 5-FU) from Day 1 to Day 14;

7. Previous use or scheduled to receive monoclonal antibodies (e.g. bevacizumab, cetuximab, etc) during the study (From Day 1 to Day 14);

8. Major surgery within the previous 3 weeks;

9. Any type of condition leading to chronic diarrhea, including but not limited to inflammatory bowel diseases (e.g. ulcerative colitis and Crohn's disease), chronic diarrhea of presumed or confirmed infectious origin and irritable bowel syndrome;

10. Any diarrhea in the 48 hours preceding study drug administration;

11. Use of anti-diarrheal agents within the 48 hours prior to study drug administration;

12. Use of laxatives within 7 days prior to study drug administration;

13. Use of antibiotics within 7 days prior to study drug administration;

14. History of chronic (= 30 consecutive days) use of laxatives;

15. Active and ongoing systemic infection;

16. Lactating woman;

17. History of hypersensitivity or allergies to drugs or compounds potentially related to this investigational drug class;

18. Previous exposure to GLP-2 or other compounds in this investigational drug class;

19. Abnormal laboratory values, including

- Aspartate aminotransferase (AST) = 5 x upper limit of normal

- Alanine aminotransferase (ALT) = 5 x upper limit of normal

- Bilirubin > 2 mg/dL (34 µmol/L)

- Creatinine > 2 mg/dL (177 µmol/L)

- Albumine < 2 g/dL (20 g/L)

- Neutrophils< 1.5 x109/L

- Platelet count < 100 x109/L;

20. Concomitant bleeding disorders;

21. Other serious concomitant illness, which could interfere with the study;

22. Patient who participated in a previous study with elsiglutide (ZP1846).

Exclusion criteria 1-9 and 12-22 will be verified at screening. Exclusion criteria 10 and 11 will be checked on Day 1 only. Exclusion criteria 12, 13 and 15 will be re-checked on Day 1.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Elsiglutide
24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
Placebo
24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy

Locations

Country Name City State
Bulgaria Department of Chemotherapy, Complex Oncology Center Ruse
Bulgaria Chemotherapy Department, Complex Oncology Center Shumen
Bulgaria Department of Chemotherapy Specialized Hospital for Active Treatment of Oncological Diseases Sofia
Bulgaria Department of Chemotherapy Specialized Hospital for Active Treatment of Oncological Diseases Sofia
Bulgaria Oncology Clinic, Multiprofile Hospital for Active Treatment "Sveta Marina" Varna
Hungary Semmelweis University, Department of Diagnostic Radiology and Oncotherapy Budapest
Hungary Kenezy Hospital, Department of Clinical Pharmacology, Infectology and Allergology Debrecen
Hungary Petz Aladar County Teaching Hospital, Center of Oncologic Radiology Hungary Gyor
Hungary Szeged Medical University Department of Oncology and Oncotherapy Szeged
Romania Dr. Constantin Opris Clinical Country Emergency Hospital Baia Mare, Department of Oncology Baia Mare Maramures County
Romania Fundeni Clinical Institute - Medical Oncology Department Bucharest
Romania Prof. Dr. Ion Chiricuta Institute of Oncology, Medical Oncology Department Cluj-Napoca Cluj County
Romania Euroclinic Oncology Center SRL - Medical Oncology Department Iasi Iasi county
Romania Sf. Ioan cel Nou Emergency Clincal County Hospital Suceava Suceava county
Russian Federation Regional Oncology Center Arkhangelsk
Russian Federation Kursk Regional Clinical Oncology Center Kursk
Russian Federation Pyatigorsk Oncology Center Pyatigorsk
Russian Federation City #9 Hospital Saint-Petersburg St. Petersburg
Russian Federation City Clinical Oncology Center Saint-Petersburg St. Petersburg
Russian Federation Regional Clinical Oncology Center - Chemotherapy Department Ulyanovsk Ulyanovsk region
Russian Federation Regional Oncology Hospital Yaroslavl

Sponsors (1)

Lead Sponsor Collaborator
Helsinn Healthcare SA

Countries where clinical trial is conducted

Bulgaria,  Hungary,  Romania,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients experiencing Diarrhea Severity of Diarrhea will be classified according to the NCI-CTCAE. Day 1 to Day 14 No
Secondary Safety and tolerability of the administered repeated doses of elsiglutide (ZP1846) will be evaluated Safety will be evaluated by monitoring:
Physical examination
Vital signs
Clinical laboratory parameters (hematology, blood chemistry, urinalysis)
12-lead ECG
AEs
Immunogenicity testing in a subset of patients
Day 1 to Day 32 Yes
Secondary PK of elsiglutide will be evaluated The followin standard PK parameters will be evaluated:
Tmax, Cmax, AUC0-t, AUC0-24, AUC0-8, t1/2Z, ?Z, CL/F, VZ/F, the effect of multiple dosing will be evaluated (accumulation ratio). Blood sampling for PK will be performed at: pre-dose, 2h, 4, 6, 12, 24 h post-dose
Day 1 to Day 5 No
See also
  Status Clinical Trial Phase
Completed NCT06283784 - Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients N/A
Recruiting NCT03851835 - Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis Phase 3
Completed NCT04003181 - The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon N/A
Completed NCT03596827 - The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection N/A
Recruiting NCT05372068 - Cement flooRs AnD chiLd hEalth (CRADLE) N/A
Completed NCT03972618 - Evaluation of the Efficacy of Sawyer Point One Filters in Schools and Homes in the Dominican Republic N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT05052489 - Registry and Clinical Observation of Children With Diarrhoeal Disease
Completed NCT02428647 - Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation N/A
Completed NCT02541695 - Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT01739231 - Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults Phase 1/Phase 2
Completed NCT01968408 - Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children Phase 3
Not yet recruiting NCT01382199 - Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients Phase 3
Completed NCT01371656 - Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Phase 3
Completed NCT01438645 - ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy N/A
Terminated NCT01472211 - Water-based Zinc Intervention Trial in Zinc Deficient Children Phase 0
Terminated NCT01048567 - Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly Phase 2
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT00760851 - Yogurt Study in Children 2-4 Years Old Attending Daycare Phase 3